Anacetrapib as a potential cardioprotective strategy

Belinda A. Di Bartolo, Stephen J. Nicholls

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)


Cholesteryl ester transfer protein (CETP) facilitates movement of esterified cholesterol between high-density lipoproteins (HDLs) and apolipoprotein B-containing lipoproteins. By virtue of their ability to raise HDL cholesterol and lower low-density lipoprotein cholesterol, pharmacological inhibitors of CETP have received considerable attention as potential new agents in cardiovascular prevention. While early studies of CETP inhibitors have demonstrated a lack of clinical efficacy and potential toxicity, development of the potent CETP inhibitor, anacetrapib, has moved forward, with emerging evidence suggesting a role in reducing cardiovascular events. The experience with anacetrapib and its potential for use in clinical practice are reviewed here.

Original languageEnglish
Pages (from-to)3497-3502
Number of pages6
JournalDrug Design, Development and Therapy
Publication statusPublished or Issued - 7 Dec 2017


  • Anacetrapib
  • Atherosclerosis
  • CETP
  • Cardiovascular disease
  • Lipids

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this